Piyatida Prasertvit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Piyatida Prasertvit has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Angkana Chareonyingwattana
Center for Medical Genomics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
1 shared publication- Penpun Wattanakrai
Ramathibodi Hospital, Mahidol University
1 shared publication
Latest Publications
- 6 August 2017
- Published by Wiley in Contact Dermatitis
- Vol. 77 (6) , 379-384
Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity
Summary: Background: Antiretroviral drug hypersensitivity in HIV patients is common. Publications have shown that Abacavir (ABC) patch testing is useful in confirming ABC hypersensitivity in 24–50% of cases with a 100% sensitivity of HLA‐B*5701 in patch test positive cases. However, Nevirapine (NVP) patch testing has not been reported.Objectives: (1) To evaluate the usefulness and safety of NVP patch testing in Thai HIV patients with NVP hypersensitivity. (2) To assess the correlation of positive patch tests with HLA‐B*3505.Patients and methods: Patients were classified into two groups: (1) study group of 20 HIV NVP hypersensitivity patients and (2) control group of 15 volunteers without NVP hypersensitivity. Both groups were patch tested with purified and commercialized form of NVP in various vehicles.Results: Two HIV patients with NVP hypersensitivity were patch test positive. All controls tested negative. Three HIV patients were positive for HLA‐B*3505 and the two patients with positive patch testing were both HLA‐B*3505 positive.Conclusions: NVP patch testing in Thai HIV patients is safe and can be used to help confirm the association between NVP and hypersensitivity skin reactions. NVP patch test results significantly correlated with HLA‐B*3505. The sensitivity of HLA‐B*3505 for positive patch test was 100%.
- 6 August 2017
- Published by Wiley in Contact Dermatitis
- Vol. 77 (6) , 379-384
Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity
Summary: Background: Antiretroviral drug hypersensitivity in HIV patients is common. Publications have shown that Abacavir (ABC) patch testing is useful in confirming ABC hypersensitivity in 24–50% of cases with a 100% sensitivity of HLA‐B*5701 in patch test positive cases. However, Nevirapine (NVP) patch testing has not been reported.Objectives: (1) To evaluate the usefulness and safety of NVP patch testing in Thai HIV patients with NVP hypersensitivity. (2) To assess the correlation of positive patch tests with HLA‐B*3505.Patients and methods: Patients were classified into two groups: (1) study group of 20 HIV NVP hypersensitivity patients and (2) control group of 15 volunteers without NVP hypersensitivity. Both groups were patch tested with purified and commercialized form of NVP in various vehicles.Results: Two HIV patients with NVP hypersensitivity were patch test positive. All controls tested negative. Three HIV patients were positive for HLA‐B*3505 and the two patients with positive patch testing were both HLA‐B*3505 positive.Conclusions: NVP patch testing in Thai HIV patients is safe and can be used to help confirm the association between NVP and hypersensitivity skin reactions. NVP patch test results significantly correlated with HLA‐B*3505. The sensitivity of HLA‐B*3505 for positive patch test was 100%.